Spleen tyrosine kinase (SYK) is a key molecule controlling apoptosis related to the activation of PI3-K/AKT, NFκB and STAT3 anti-apoptotic signalling pathways in leukaemia type B. Uckun and Qazi [16] carried out a research study where they proposed that SYK might overcome the resistance of malignant B-lineage lymphoid cells to apoptosis providing the theory for more effective multi-modality treatment-therapy regimens for poor prognosis B-precursor ALL (BPL). Here, AKT1 is linked to acute lymphoblastic leukemia.